Bionik Laboratories (BNKL) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access BNKL Annual Balance Sheets →
The data below summarizes Bionik Laboratories's balance sheet position from Mar 31 2022 to Mar 31 2023, enabling a period-by-period comparison of financial strength.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2023)
(Dec 31 2022) (Sep 30 2022) (Jun 30 2022) (Mar 31 2022)
Assets
Cash & cash equivalent0.43
Cash & Short-term Investments0.00
Accounts receivable0.45
Inventories1.03
Other Current Assets0.00
Prepaid Expense And Other Assets Current0.86
Total Current Assets2.78
Equipment/Property/Plant Net0.19
Goodwill net0.10
Intangible Assets0.03
Other Assets, Noncurrent0.26
Total Assets3.36
Liabilities
Accounts Payable, Current AC0.56
Accrued Liabilities, Current AC1.39
Other Liabilities, Current0.36
Total Current Liabilities2.31
Convertible Notes Payable, Noncurrent LO2.16
Total Long-term Debt2.16
Other liabilities, Noncurrent0.54
ContractWithCustomerLiabilityNoncurrent0.30
Contract With Customer Liability Current0.34
Total Liabilities5.00
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock98.67
Retained Earnings / Accumulated Deficit-100.35
Other Equity0.03
Common Stockholder's Equity-1.64
Total Stockholder's Equity-1.64
Liabilities & Stockholder's Equity3.36
4 historic quarters locked

Sign in to unlock the full Bionik Laboratories balance sheet history.

About Bionik Laboratories Corp Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001410578-23-001453

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.